Company Profile
Enanta Pharmaceuticals
Company Overview
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
Company History
Enanta is a clinical stage biotechnology company dedicated to creating oral drugs with an emphasis on indications in virology and immunology. Our story began in 1995 when we grew from humble beginnings to the company we are today — one that collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie combination regimen for chronic hepatitis C virus infection (glecaprevir in MAVYRET® and paritaprevir in VIEKIRA PAK®). We have also developed clinical candidates in nonalcoholic steatohepatitis, hepatitis B virus and SARS-CoV-2. Currently our clinical programs are focused on respiratory syncytial virus and our earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.
Notable Accomplishments / Recognition
Enanta has discovered novel protease inhibitors for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enanta’s collaboration with AbbVie, include glecaprevir and paritaprevir.
AbbVie is responsible for all worldwide commercialization of paritaprevir-containing and glecaprevir-containing treatment regimens for HCV.
Benefits
Enanta currently offers eligible employees a comprehensive benefits package that includes the following:
Comprehensive Health Plan including medical and dental coverage
401(k) Retirement Plan
Flexible Spending Account
Life Insurance & AD&D
Short and Long-term Disability coverage
Tuition Assistance
Paid Vacation and Flex Days
Paid Holidays
Jury Duty
Work / Life Balance and Employee Assistance Plan